Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juni 2020

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • nohopeN Offline
    nohopeN Offline
    nohope
    wrote on sidst redigeret af
    #1837

    You are welcome 😉

    1 Reply Last reply
    0
    • B Offline
      B Offline
      BioShare
      wrote on sidst redigeret af
      #1838

      Genmab har bare været super stærk igen i dag...der er efter min opfattelse helt klart et par store spillere på banen med kursmål betydeligt højere oppe. Ellers havde vi smidt højde i sidste uge...og i dag for den sags skyld.

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #1839

        it is just a sign of nohope's market influence; big players stepped in immediately after his comment 😉

        1 Reply Last reply
        0
        • H Offline
          H Offline
          henrik48
          wrote on sidst redigeret af
          #1840

          Helt enig...lad os slutte dagen med en forrygende slutauktion 🙂

          1 Reply Last reply
          0
          • B Offline
            B Offline
            BioShare
            wrote on sidst redigeret af
            #1841

            ---haha...yes, and suddenly they saw hope and
            that there were no errors in the spreadsheets 🙂

            1 Reply Last reply
            0
            • B Offline
              B Offline
              BioShare
              wrote on sidst redigeret af
              #1842

              Et fornuftigt luk i kurs 2.169 er meget tilfredsstillende - selvom volumen var relativ lav i dag. Lad se om US kan holde pace i løbet af aftenen, så skulle kurs 2.200 kommer i spil i morgen. VIX er også suset ned i forhold til tidligere på dagen, index ok...og NBI i bedring med et lille forsigtigt +-.

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #1843

                "We have moved to our new state-of-the-art offices and translational research laboratories! We look forward to welcoming our experts involved in discovery, development & commercialization of next-generation antibodytherapeutics to our new home, as per local guidance on COVID-19 https://twitter.com/Genmab/status/1277626056946724864
                .

                1 Reply Last reply
                0
                • H Offline
                  H Offline
                  HSK
                  wrote on sidst redigeret af
                  #1844

                  Så’ der nyt

                  1 Reply Last reply
                  0
                  • H Offline
                    H Offline
                    HSK
                    wrote on sidst redigeret af
                    #1845

                    Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

                    1 Reply Last reply
                    0
                    • H Offline
                      H Offline
                      HSK
                      wrote on sidst redigeret af
                      #1846

                      24 percent confirmed objective response rate (ORR) by independent central review (95% Confidence Interval: 15.9% - 33.3%) with a median duration of response (DOR) of 8.3 months.

                      1 Reply Last reply
                      0
                      • H Offline
                        H Offline
                        HSK
                        wrote on sidst redigeret af
                        #1847

                        “These promising topline data from innovaTV 204 will be the basis of further engagement with the U.S. FDA as we continue to progress and expand our tisotumab vedotin development program in solid tumors with our partner.”

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #1848

                          Fine data

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #1849

                            Succeskriteriet var 20% og 6 mdr

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #1850

                              Og det her er kun monoterapi. Herefter følger kombi-studierne.

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #1851

                                link til meddelelsen https://ir.genmab.com/news-releases/news-release-details/genmab-announces-very-favorable-topline-results-phase-2-clinical

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #1852

                                  $36,8 i eftermarkedet=2440

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #1853

                                    sgen stiger 2,5% i eftermarkedet

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #1854

                                      Det burde give lidt medvind i morgen

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #1855

                                        Eftermarkedseuforien aftager noget, nu $33,52

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          BioShare
                                          wrote on sidst redigeret af
                                          #1856

                                          Ja, og nu i minus...så det after market tror jeg ikke rigtig på i aften. Men forventer til gengæld niveauet 2.240-2.250 i morgen. Havde godt nok være voldsomt med kurs 2.440..men der skal vi nok vente helt til jul 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger